Vaniqa
indicated to support the reduction of unwanted facial hair growth in women.
Strengths: 13.9%
Where to Check Availability
Medicine details
- Conditions
- Therapeutic class
Ornithine Decarboxylase Inhibitor
- Pharmacological class
Ornithine Decarboxylase Inhibitor
- Contraindications
hypersensitivity to eflornithine
- Precautions and warnings
avoid contact with eyes or mucous membranes; discontinue if irritation occurs
- Minor side effects
skin irritation; stinging sensation; burning sensation
- Moderate side effects
dry skin; acne; ingrown hair
- Serious side effects
anaphylaxis — requires immediate medical attention
- Dosage forms
Cream
- Administration route
Cutaneous use
- Patient summary
indicated to support the reduction of unwanted facial hair growth in women.
- Prescription status
POM
- Manufacturer
Almirall
- Onset Time
4–8 weeks
- Duration
Continuous use
- Storage instructions
Store below 25°C. Do not freeze.
- Age restrictions
Not indicated for use in paediatric patients.
Mechanism of action
It works by inhibiting the enzyme ornithine decarboxylase in the hair follicle, which is required for hair cell division, thereby slowing the rate of hair growth.
Pregnancy and breastfeeding
Pregnancy: Not recommended unless clearly necessary. Breastfeeding: Use with caution as it is unknown if it passes into breast milk.
Vaniqa
indicated to support the reduction of unwanted facial hair growth in women.
Editorial Notes
- Active ingredient(s): Eflornithine
- Listed indication(s): Hirsutism
Available option
- 2 tubes - 13.9 %1289-13-9-pct-15409